Philosophy of Care
Dr. Rashmi Verma is an adult medical oncologist who specializes in medical treatment of genitourinary malignancies including kidney/renal cell, bladder, prostate, ureteral cancers, testicular cancers.
She is a strong advocate for patients and believes in treating not only the medical condition but patient in total.
Each patient requires a varied amount of physical, emotional, psychological, and social support. She believes that patient has equal right in making decisions regarding treatment options.
Dr. Rashmi Verma believes in providing comprehensive care to patients such as options for immuno-oncology, mutational profiling, regional therapies, clinical trials and supportive care.
She believes that positive thinking besides novel treatment strategy is best therapy!
Dr. Rashmi Verma is an adult medical oncologist who specializes in medical treatment of genitourinary cancers including kidney/renal cell, bladder, prostate, ureteral and testicular cancer/germ cell tumor.
Dr. Rashmi Verma is interested in conducting clinical trials for these malignancies and has a particular interest in novel treatments for prostate, renal, and bladder cancer including targeted therapies, immunotherapies.
Also, she is interested and involved in clinical education of medical students, residents and fellows.
Hematology and Oncology
M.B.B.S., University College of Medical Sciences, Delhi University, Delhi, India 1994
Internship: Internal Medicine (PGY1-2), University of South Dakota and VA Hospital, Sioux Falls SD 2009-2011
Internal Medicine (PGY3), University of Medicine and Dentistry of New Jersey and Cooper University Hospital, Camden NJ 2011-2012
Hematology & Oncology, Texas Tech University, Lubbock TX 2013-2016
American Board of Hematology,
American Board of Internal Medicine,
American Board of Medical Oncology,
American College of Physicians (ACP)
American Society of Clinical Oncology (ASCO)
Association of Northern California Oncologists
California Cancer Consortium
Southwest Oncology Group
Honors and Awards
Chief Fellow during Hematology & Oncology Fellowship,
Fellow of American College of Physicians,
Select Recent Publications
Verma R. Neoadjuvant Cabozantinib in Renal Cell Carcinoma: A Case Series and Review of Literature. Clinical Genitourinary Journal. 2020 April.
Mirandola L, Wade R, Verma R, Et al. Sex-driven differences in immunological responses: challenges and opportunities for the immunotherapies of the third millennium. Int Rev Immunol. 2015 Mar;34(2):134-42.
Verma R. Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection. Current Cancer Drug Targets. 2015;15(7):575-92.
Cobos E, Figueroa J, Mirandola L, Verma R. International Reviews of Immunology: co-author: The Role of Human Papilloma Virus (HPV) Infection in Non- Anogenital cancer and the Promise of Immunotherapy: A Review. International Reviews of Immunology. 2014;33(5).
Riaz J, Verma R, et al. Cancer testis antigens: Potential new targets for lung cancer. MirandolaL. Journal of Clinical Oncology. 2014;32:15.
Riaz J, Verma R, Mirandola L, et al. Effect of the novel galectin-3 blocker, Gal3M, on the efficacy and reduction of toxicity of proteasome inhibitors for the treatment of multiple myeloma. Journal of Clinical Oncology. 2014;32:15 SUPPL. 1
Verma R, Riaz J, et al. Effect of galectin-3 inhibition on drug resistance, motility, invasion, and angiogenic potential in ovarian cancer. Journal of Clinical Oncology. 2014;32:15 SUPPL. 1
Lynch DW, Verma R, Larson E et al. Primary cutaneous mantle cell lymphoma with blastic features: report of a rare case with special reference to staging and effectiveness of chemotherapy. J Cutan Pathol. 2012 Apr;39(4):449.
Gupta BK, Maher DM, Ebeling M, Verma R, et al. MUC13 expression enhances colon cancer progression. Cancer Research. 2011;71:8 SUPPL. 1